Jacques Dumas
Overview
Explore the profile of Jacques Dumas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
1594
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Michot N, Guyochin A, Cinier M, Savignard C, Kitten O, Pascual M, et al.
Peptides
. 2022 Feb;
152:170760.
PMID: 35150805
A new strategy of peptide half-life extension has been evaluated. We investigated libraries of a small and very stable protein scaffold called Nanofitin, capable of high affinity for protein targets....
2.
Dumas J, Severac A, Lemoine C, Huille S, Rak A, Prades C
Med Sci (Paris)
. 2020 Jan;
35(12):1171-1174.
PMID: 31903933
Therapeutic antibodies generation has to be faster with less development costs. This requires combination of in silico predictions associated with cutting edge screening and characterization technologies. Here, non-exhaustive examples illustrate...
3.
Dumas J, Huille S, Prades C
Med Sci (Paris)
. 2020 Jan;
35(12):1163-1170.
PMID: 31903932
The therapeutic antibodies and their by-products (antibody fragments, conjugated, etc.) establish one of the most dynamic biopharmaceutical market segments today. Due to their intrinsic properties of specificity towards their target,...
4.
Cassotta A, Mikol V, Bertrand T, Pouzieux S, Le Parc J, Ferrari P, et al.
Nat Med
. 2019 Sep;
25(9):1402-1407.
PMID: 31501610
Natalizumab (NZM), a humanized monoclonal IgG4 antibody to α4 integrins, is used to treat patients with relapsing-remitting multiple sclerosis (MS), but in about 6% of the cases persistent neutralizing anti-drug...
5.
Fyfe C, LeBlanc G, Close B, Nordmann P, Dumas J, Grossman T
Antimicrob Agents Chemother
. 2016 Aug;
60(11):6989-6990.
PMID: 27550359
No abstract available.
6.
Doig P, Boriack-Sjodin P, Dumas J, Hu J, Itoh K, Johnson K, et al.
Bioorg Med Chem
. 2014 Sep;
22(21):6256-69.
PMID: 25262942
An aminoquinazoline series targeting the essential bacterial enzyme GlmU (uridyltransferase) were previously reported (Biochem. J.2012, 446, 405). In this study, we further explored SAR through a combination of traditional medicinal...
7.
Moulin A, Mathieu M, Lawrence C, Bigelow R, Levine M, Hamel C, et al.
Protein Sci
. 2014 Sep;
23(12):1698-707.
PMID: 25209176
Various important biological pathways are modulated by TGFβ isoforms; as such they are potential targets for therapeutic intervention. Fresolimumab, also known as GC1008, is a pan-TGFβ neutralizing antibody that has...
8.
Sauvage E, Derouaux A, Fraipont C, Joris M, Herman R, Rocaboy M, et al.
PLoS One
. 2014 May;
9(5):e98042.
PMID: 24875494
In Escherichia coli, penicillin-binding protein 3 (PBP3), also known as FtsI, is a central component of the divisome, catalyzing cross-linking of the cell wall peptidoglycan during cell division. PBP3 is...
9.
Martinez-Botella G, Breen J, Duffy J, Dumas J, Geng B, Gowers I, et al.
J Med Chem
. 2012 Oct;
55(22):10010-21.
PMID: 23043329
Thymidylate kinase (TMK) is an essential enzyme in bacterial DNA synthesis. The deoxythymidine monophosphate (dTMP) substrate binding pocket was targeted in a rational-design, structure-supported effort, yielding a unique series of...
10.
Keating T, Newman J, Olivier N, Otterson L, Andrews B, Boriack-Sjodin P, et al.
ACS Chem Biol
. 2012 Aug;
7(11):1866-72.
PMID: 22908966
There is an urgent need for new antibacterials that pinpoint novel targets and thereby avoid existing resistance mechanisms. We have created novel synthetic antibacterials through structure-based drug design that specifically...